Free Trial
Daniel Arias

Daniel Arias Analyst Performance

Managing Director at Stifel Nicolaus

Daniel Arias is a stock analyst at Stifel Nicolaus focused in the medical sector, covering 13 publicly traded companies. Over the past year, Daniel Arias has issued 14 stock ratings, including buy and hold recommendations. While full access to Daniel Arias' proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Daniel Arias' coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
20 Last 9 Years
Buy Recommendations
55.00% 11 Buy Ratings
Companies Covered
13 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy55.0%11 ratings
Hold40.0%8 ratings
Sell5.0%1 ratings

Out of 20 total stock ratings issued by Daniel Arias at Stifel Nicolaus, the majority (55.0%) have been Buy recommendations, followed by 40.0% Hold and 5.0% Sell.

Exchange Coverage

ExchangePercentageCount
NASDAQ
69.2% of companies on NASDAQ
9 companies
NYSE
30.8% of companies on NYSE
4 companies

Daniel Arias, an analyst at Stifel Nicolaus, currently covers 13 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
12 companies
92.3%
Computer and Technology
1 company
7.7%

Daniel Arias of Stifel Nicolaus specializes in stock coverage within the Medical sector, with additional focus on Computer and Technology companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
6 companies
46.2%
MEDICAL SERVICES
3 companies
23.1%
INSTRU - SCIENTFC
1 company
7.7%
MED INSTRUMENTS
1 company
7.7%
MEDICAL INFO SYS
1 company
7.7%
ANALYTICAL INSTRUMENTS
1 company
7.7%

About Daniel Arias

Dan Arias joined Stifel in June 2019. He is a Managing Director in the Healthcare sector, covering Life Sciences and Diagnostics. Before joining Stifel, Dan previously covered Life Sciences and Diagnostics at Citigroup and UBS. He previously worked in the research microbiology lab at Wyeth Pharmaceuticals. Dan is a graduate of Mary Washington College and Rutgers Business School.
Follow on LinkedIn

Daniel Arias' Ratings History at Stifel Nicolaus

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Bruker Corporation stock logo
BRKR
Bruker
8/5/2025Set Price Target$34.72$40.00Hold
Avantor, Inc. stock logo
AVTR
Avantor
8/4/2025Set Price Target$11.41$12.00Hold
Revvity Inc. stock logo
RVTY
Revvity
7/29/2025Lower Price Target$95.66$110.00Hold
Bruker Corporation stock logo
BRKR
Bruker
5/8/2025Lower Price Target$40.95$48.00Hold
Bio-Techne Corp stock logo
TECH
Bio-Techne
5/8/2025Lower Price Target$48.76$60.00Hold
Guardant Health, Inc. stock logo
GH
Guardant Health
5/1/2025Boost Price Target$48.06$60.00Buy
Avantor, Inc. stock logo
AVTR
Avantor
4/28/2025Downgrade$12.93$14.00Hold
Thermo Fisher Scientific Inc. stock logo
TMO
Thermo Fisher Scientific
4/24/2025Lower Price Target$422.94$620.00Buy
Danaher Corporation stock logo
DHR
Danaher
3/14/2025Upgrade$203.96$260.00Buy
MaxCyte, Inc. stock logo
MXCT
MaxCyte
3/12/2025Lower Price Target$3.47$9.00Buy
Guardant Health, Inc. stock logo
GH
Guardant Health
2/21/2025Boost Price Target$45.85$53.00Buy
Bruker Corporation stock logo
BRKR
Bruker
2/14/2025Lower Price Target$50.29$57.00Hold
10x Genomics stock logo
TXG
10x Genomics
2/13/2025Lower Price Target$11.52$18.00Buy
Avantor, Inc. stock logo
AVTR
Avantor
2/10/2025Lower Price Target$19.15$26.00Buy